MEK inhibition remodels the immune landscape of mutant KRAS tumors to overcome resistance to PARP and immune checkpoint inhibitors

Mutant KRAS tumors are associated with poor outcomes at least in part due to decreased therapeutic sensitivity. Here we show that KRAS mutations are associated with resistance to monotherapy and combination therapy with Poly-(ADP-ribose) polymerase inhibitors (PARPi) and immune checkpoint blockade w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Yang, Bin, Li, Xi, Fu, Yu, Guo, Ensong, Ye, Youqiong, Li, Fuxia, Liu, Si, Xiao, Rourou, Liu, Chen, Lu, Funian, Huang, Jia, Qin, Tianyu, Han, Leng, Peng, Guang, Mills, Gordon B., Sun, Chaoyang, Chen, Gang
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265237/
https://ncbi.nlm.nih.gov/pubmed/33589518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2370
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados